Center for Translational Viral Oncology (CTVO)

摘要 第二阶段的续签是以“翻译病毒肿瘤学中心”(CTVO)之前的成功为前提的。 基于不断发展的研究主题，这些主题利用了新的教员专业知识和健康状况不同、容易患癌症的 我们地区的人口。病毒诱导的恶性肿瘤，如人乳头瘤病毒(HPV)诱导的 生殖器肉瘤和与KSHV相关的卡波西肉瘤在路易斯安那州高度流行，且发病率增加 艾滋病毒携带者的发病率。考虑到地区对病毒癌症研究的需要，CTVO第二阶段是必不可少的 1)维持有才华的初级首席调查员的职业发展；2)支持现有和 联合病毒肿瘤学区域科学家之间的研究；以及3)加强制度化 生产性核心设施。CTVO的首要目标是改善疾病管理和生活质量 通过响应性的研究活动覆盖路易斯安那州不同的癌症患者谱系。我们的直接客户 目标是全面准备年轻研究人员进行尖端病毒肿瘤学研究 并更好地定义艾滋病毒合并感染是如何诱发许多恶性肿瘤的。作为这一目标的一部分，CTVO将 继续加强路易斯安那州立大学新分校现有癌症病毒学和Cobre项目之间的合作 奥尔良、路易斯安那州立大学巴吞鲁日分校、路易斯安那州立大学什里夫波特分校和杜兰大学 作为路易斯安那州IDEA生物医学研究卓越网络(INBRE)的一部分。CTVO将 通过提供：(I)辅导组，支持初级绩效指标的科学、指导和行政需求 由美国国立卫生研究院资助的基础科学和临床研究人员组成，致力于指导JPI研究项目 实施和职业发展；(2)独特的临床材料，包括带注释的生物显微镜 收集自纽约大学医学中心的HIV+和HIV病毒相关癌症患者 奥尔良；(Iii)辅助性行政核心(管理)，以促进指导网络、职业 发展和关键的外部评估；(4)动态研究核心设施，包括艾滋病毒临床 肿瘤生物库(HCTB)，分子组织病理学/分析显微镜核心(MHAM)，细胞 免疫学/代谢组学核心(CIMC)，翻译基因组学核心(TGC)，以及生物统计和 生物信息学核心(BBC)，专门为协助最先进的JPI研究工作而设计。 CTVO将这一结构集中在JPI领导的四个研究项目上，这四个项目1)研究艾滋病毒-1的S对免疫的影响 重新编程以预防肿瘤，2)寻求定义卡波西肉瘤的分子基础- 相关疱疹病毒潜伏期与肿瘤发生，3)研究人乳头状瘤 人类乳头状瘤病毒(HPV)和EB病毒(EBV)在肛门癌中的感染情况，以及4)人类 内源性逆转录病毒(HERV)表达与胶质母细胞瘤干细胞及耐药性的关系最后，一位飞行员 随后将实施研究计划，以支持将促进CTVO动态增长的重点研究。

ABSTRACT This Phase 2 renewal is premised upon the prior success of the “Center for Translational Viral Oncology” (CTVO) and upon evolving research themes that leverage new faculty expertise and health-disparate, cancer prone populations in our region. Virus-induced malignancies, such as human papilloma virus (HPV)-induced anogenital, and KSHV-associated Kaposi Sarcomas are highly prevalent in Louisiana and occur at increased incidence in people living with HIV. Given the regional need for viral cancer research, CTVO Phase 2 is essential to: 1) sustain the career development of talented Junior Principal Investigators (JPIs); 2) to support existing and coalescing research between regional scientists in viral oncology; and 3) to reinforce the institutionalization of productive core facilities. The overarching goal of CTVO is to improve disease management and quality of life across the diverse spectrum of Louisiana cancer patients through responsive research activity. Our immediate goal is to comprehensively prepare young investigators to conduct cutting edge viral oncology research and to better define how HIV co-infection predisposes many malignancies. As part of this goal CTVO will continue to reinforce collaborations between existing cancer virology and COBRE programs at LSU New Orleans, LSU Baton Rouge, LSU Shreveport, and Tulane University, to form a highly productive collaborative network, as part of the Louisiana IDeA Networks of Biomedical Research Excellence (INBRE). The CTVO will support the scientific, mentoring and administrative needs of the JPIs by providing (i) mentoring teams composed of NIH-funded basic science and clinical investigators dedicated to guiding JPI research project implementation and career development; (ii) unique clinical material consisting of annotated biospecimens collected from HIV+ and HIV- patients with virus-associated cancers at the University Medical Center, New Orleans; (iii) a supportive administrative core (ADMIN) to facilitate mentoring networking, career development, and critical external evaluation; (iv) dynamic research core facilities including the HIV clinical tumor biorepository (HCTB), a molecular histopathology/analytical microscopy core (MHAM), a cellular immunology/metabolomics core (CIMC), a translational genomics core (TGC), and a biostatistics and bioinformatics core (BBC), which were specifically designed to assist in state-of-the-art JPI research endeavors. CTVO focuses this structure on four JPI-led research projects that 1) study HIV-1's impact on immune reprogramming to predispose neoplasia, 2) seek to define the molecular underpinnings of Kaposi's Sarcoma- associated herpesvirus (KSHV) latency and tumorigenesis, 3) investigate interactions between human papilloma virus (HPV) and Epstein–Bar virus (EBV) in anogenital cancer, and 4) test relationships between human endogenous retroviral (HERV) expression and glioblastoma stemness and drug resistance. Finally, a pilot research program will ensue to support focused research that will promote CTVO dynamic growth.